177Lu PSMA vs Cabazitaxel for mCRPC: ... - Fight Prostate Ca...

Fight Prostate Cancer

3,036 members1,517 posts

177Lu PSMA vs Cabazitaxel for mCRPC: real-world data

Maxone73 profile image
0 Replies

In a nutshell....

If you can get both, get both (median OS = 29.6 months)

If you have to choose, choose 177Lu-PSMA (median OS 16.5 vs 14.7 months for cabazitaxel alone)

I am not sure it's a meaningful impact, I would try to get both, but I must find if they can give an indication about the sequeence.

More details here: prostatewarriors.com/2025/0...

Written by
Maxone73 profile image
Maxone73
To view profiles and participate in discussions please or .
Read more about...

Not what you're looking for?

You may also like...

Phase 3 ended: ECLIPSE trial of 177Lu-PSMA-I&T

A phase 3 clinical trial called ECLIPSE has shown that 177Lu-PSMA-I&T significantly extends the...
Maxone73 profile image

Apalutamide as first-line treatment, real-world data

Because sometimes it's nice to know the actual outcomes in day to day clinical practice. A...
Maxone73 profile image

Phase 1 ACCEL trial recruiting: AC-225-PSMA-62 for OLIGOMETASTATIC HSPC and mCRPC

I am not oligometastatic, dammit! But this could really be something worth trying! It is, at least...
Maxone73 profile image

ASCO Gu 2025: real world data confirms that undetectable PSA nadir is a strong predictor of outcomes

Real world seems to confirm clinical trial data in this case! A real-world study from the IRONMAN...
Maxone73 profile image

AMG 509 (Xaluritamig) updates about the clinical trial

A Phase 3 trial is recruiting 675 patients to be randomized to Xaluritamig versus cabazitaxel or an...
Maxone73 profile image

Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.

Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.